Treatment of human brucellosis with netilmicin and doxycycline

Clinical Infectious Diseases

Volumn 22, Issue 3, 1996, Pages 441-445

  Solera, Javier ^a   Espinosa, Alfredo ^b   Geijo, Paloma ^b   Martínez Alfaro, Elisa ^b   Sáez, Lourdes ^b   Sepúlveda, Maria Antonia ^b   Ruiz Ribó, Mariá Dolores ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GLYCERYL TRINITRATE; NETILMICIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BRUCELLOSIS; CLINICAL TRIAL; DRUG EFFICACY; EYE TOXICITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENCE RISK; SACROILIITIS; SPLEEN ABSCESS; SPLENECTOMY; SPONDYLITIS; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

EID: 0029775212     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.3.441     Document Type: Article

References (22)

1. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:2053-60.
2. Hall WH. Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1990;12:1060-99.
3. Joint Food and Agriculture Organization, World Health Organization. FAO-WHO Expert Committee on Brucellosis. 6th report. WHO technical report series, no. 740. Geneva: World Health Organization, 1986:56-7.
4. Solera J, Martinez-Alfaro E, Saez L, Gil A, del Rey Calero J. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A meta-analysis of randomized controlled trials [abstract no. M74]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994:261.
5. Lubani MM, Dudin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J 1989;8:75-8.
6. Madkour MM. Treatment. In: Madkour MM, ed. Brucellosis. London: Butterworths, 1989:219-43.
7. Gotuzzo E, Carrillo C, Cellillo C. Brucella. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases. Philadelphia: WB Saunders, 1992;1513-21.
8. Kumana CR, Yuen KY. Patenteral aminoglycoside therapy. Selection, administration and monitoring. Drugs 1994;47:902-13.
9. Solera J, Medrano F, Rodriguez M, Geijo P, Paulino J. Ensayo terapéutico comparative y multicéntrico de rifampicina y doxiciclina frente a estreptomicina y doxiciclina en la brucelosis humana. Med Clin (Bare) 1991;96:649-53.
10. Hausler WJ Jr, Moyer NP, Holcomb LA. Brucella. In: Lennette EH, Balows A, Hausler WJ Jr, Shadomy HJ, eds. Manual of clinical microbiology. 4th ed. Washington, DC: American Society for Microbiology, 1984:382-6.
11. Dean AG, Dean JA, Coulombier D, et al. Epi Info, version 6: a word processing, database, and statistics program for epidemiology on microcomputers. Atlanta: Centers for Disease Control and Prevention, 1994.
12. Solera J, Rodríguez-Zapata M, Geijo P, et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemother 1995;39:2061-7.
13. Ariza J, Gudiol F, Pallarés R, Rufi G, Femández-Viladrich P. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother 1985;28:548-51.
14. Acocella G, Bertrand A, Beytout J, et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother 1989;23:433-9.
15. Colmenero Castillo JD, Hernández Marquez S, Reguera Iglesias JM, Cabrera F, Ruiz Diaz F, Alonso A. Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis. Chemotherapy 1989;35:146-52.
16. Cisneros JM, Viciana P, Colmenero J, Pachon J, Martinez C, Alarcón A. Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks and streptomycin for 2 weeks. Antimicrob Agents Chemother 1990;34:881-3.
17. Montejo JM, Alberola I, Glez-Zarate P, et al. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 1993;16:671-6.
18. Ariza J, Gudiol F, Pallares R, et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin: a randomized, double-blind study. Ann Intern Med 1992;117:25-30.
19. Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995;20:1241-9.
20. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. In: Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:279-306.
21. de Vries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990;9:161-8.
22. Parker SE, Davey PG. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother 1993;31:4-8.